Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a …
…, EMJ Brouwers-Kuyper, AHH Bongaerts… - The Lancet, 2002 - thelancet.com
Background Diagnostic strategies for pulmonary embolism are complex and consist of non-invasive
diagnostic tests done to avoid conventional pulmonary angiography as much as …
diagnostic tests done to avoid conventional pulmonary angiography as much as …
89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
…, TH Oude Munnink, AH Brouwers, AHH Bongaerts… - Clinical Cancer …, 2014 - AACR
Purpose: HSP90 chaperones have key client proteins that are involved in all hallmarks of
breast cancer growth and progression. The primary aim of this clinical trial was to evaluate the …
breast cancer growth and progression. The primary aim of this clinical trial was to evaluate the …
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic …
…, WJ Sluiter, RA Dierckx, AHH Bongaerts… - Journal of Nuclear …, 2015 - Soc Nuclear Med
No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell
carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be …
carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be …
Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors
…, AH Brouwers, AHH Bongaerts… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Everolimus increases progression-free survival in patients with advanced neuroendocrine
tumors (NETs). Currently, no biomarkers are available for early selection of patients who will …
tumors (NETs). Currently, no biomarkers are available for early selection of patients who will …
18F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients
…, EFJ de Vries, AHH Bongaerts… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However,
knowledge about varying expression across metastases and surrounding normal tissue in …
knowledge about varying expression across metastases and surrounding normal tissue in …
Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies
…, AWJM Glaudemans, AHH Bongaerts… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment…
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment…
Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients
…, A van der Schaaf, LV van Dijk, AHH Bongaerts… - Radiotherapy and …, 2016 - Elsevier
Background and purpose Curative radiotherapy for prostate cancer may lead to anorectal side
effects, including rectal bleeding, fecal incontinence, increased stool frequency and rectal …
effects, including rectal bleeding, fecal incontinence, increased stool frequency and rectal …
ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment
…, JA Gietema, CP Schröder, AHH Bongaerts… - Clinical Cancer …, 2016 - AACR
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers,
making it a potential drug target. We performed an 89 Zr-PET imaging study with …
making it a potential drug target. We performed an 89 Zr-PET imaging study with …
Low incidence of nephropathy in surgical ICU patients receiving intravenous contrast: a retrospective analysis
JW Haveman, RT Gansevoort, AHH Bongaerts… - Intensive care …, 2006 - Springer
Objective Various studies have documented a markedly high incidence of contrast-induced
nephropathy (CIN). Most of these studies were conducted in patients not in the ICU. In ICU …
nephropathy (CIN). Most of these studies were conducted in patients not in the ICU. In ICU …
Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT
…, HJG Arts, NM Jager, AHH Bongaerts… - Journal of Nuclear …, 2015 - Soc Nuclear Med
The estrogen receptor α (ERα) is expressed in approximately 70% of ovarian cancer tumors.
PET of tumor ERα expression with the tracer 16α- 18 F-fluoro-17β-estradiol ( 18 F-FES) may …
PET of tumor ERα expression with the tracer 16α- 18 F-fluoro-17β-estradiol ( 18 F-FES) may …